

Access to isoindole-derived BODIPYs by an aminopalladation cascade

Heinrich F. von Köller^a, Finn J. Geffers^b, Pedram Kalvani^a, Adrian S. Foraita^b, Patrick-Eric J. Loß^b, Burkhard Butschke^c, Peter G. Jones^d and Daniel B. Werz^{a*}

^aAlbert-Ludwigs-Universität Freiburg,
Institute of Organic Chemistry
Albertstr. 21, 79104 Freiburg, Germany

^bTechnische Universität Braunschweig,
Institute of Organic Chemistry
Hagenring 30, 38106 Braunschweig, Germany

^cAlbert-Ludwigs-Universität Freiburg,
Institute of Inorganic and Analytical Chemistry,
Albertstr. 21, 79104 Freiburg, Germany

^dTechnische Universität Braunschweig,
Institute of Inorganic and Analytical Chemistry
Hagenring 30, 38106 Braunschweig, Germany

(*corresponding author: daniel.werz@chemie.uni-freiburg.de)

Table of Contents

1. General Experimental	2
2. Spectroscopic data	3
3. Deviation tables.....	4
4. General Procedures	6
5. Starting Material Synthesis.....	10
5.1. Overview	10
5.2. Ketone Precursors.....	11
5.3. Oxime Intermediates	18
5.4. Oximester Precursors	25
6. BODIPYs.....	49
6.1. <i>meso</i> -Aryl BODIPYs.....	49
6.2. <i>meso</i> -Alkynyl-BODIPYs.....	97
7. Crystal Structure Determinations	121
8. References.....	125

1. General Experimental

All solvents were distilled before use and stored over molecular sieves unless otherwise stated. Air- and moisture-sensitive reactions were carried out in oven-dried or flame-dried glassware, septum-capped under atmospheric pressure of argon. Commercially available compounds were used without further purification unless otherwise stated. For all purifications by column chromatography on silica gel silica gel Geduran Si 60 (40-63 μm pore size) from Merck, or Silica 60 (40-63 μm pore size) from Macherey-Nagel was used. Reactions were heated in an aluminium heating block with silicon oil in the vial slots.

Proton (^1H), carbon (^{13}C), fluorine (^{19}F), and boron (^{11}B) NMR spectra were recorded on a Bruker AVIII300, Bruker AVIII400, Bruker AVIIHD500, Bruker DRX500, or Bruker AVII600 instrument using the residual signals from CHCl_3 , $\delta = 7.26$ ppm and $\delta = 77.16$ ppm as internal reference for ^1H and ^{13}C chemical shifts, respectively. Additionally, tetramethylsilane (TMS; $\delta = 0.00$ ppm; 0.03%) was added to NMR samples. The following abbreviations were used for ^1H , ^{13}C , ^{19}F , and ^{11}B NMR chemical shifts: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet. The chemical shift δ is given in ppm. ESI-HRMS was carried out on an Exactive (Thermo Scientific) Orbitrap instrument. IR spectra were recorded on a thin film spectrometer Tensor 27 from Bruker, or on an FT-IR Paragon 1000 from Perkin Elmer as thin films. Melting points of solid products were recorded on a Schorpp MPM-HV2, or on a Büchi SMP-20 melting point meter. Exact reaction conditions are given in the following procedures. UV-vis and fluorescence spectra were measured on a Varian Cary 100 Bio photometer with temperature control or a Shimadzu UV-1900i and a Varian Cary Eclipse fluorescence spectrophotometer or a Jasco FP-8300, respectively. Fluorescence excitation spectra were measured but are not shown. The spectra were shown to be comparable to the UV-vis spectra of the corresponding compound. No significant discrepancy was observed. Absolute fluorescence quantum yields were determined using a spectrofluorometer (Edinburgh Instruments, FS5) with an integrating sphere.

2. Spectroscopic data


Table S1. Spectroscopic data at room temperature of a selection of prepared compounds in dichloromethane.^[a]

	λ_{max}^A [nm]	λ_{max}^F [nm]	ϵ [$10^3 \text{ M}^{-1} \text{ cm}^{-1}$]	$\Delta\tilde{\nu}$ [cm^{-1}]	$\phi_F(\text{RT})$
5a	540	571	50.3	1005	0.03
5b	517	542	38.1	892	0.04
5e	547	599	42.7	1587	0.01
5f	519	545	35.4	919	0.04
6a	582	617	21.7	975	0.61
6e	564	602	13.9	1119	0.59
6f	544	574	24.1	961	0.84
5k	459	530	15.8	2919	< 0.01
5l	434	507	16.2	3318	< 0.01

[a] All measurements were performed in CH_2Cl_2 . λ^A = absorption wavelength, λ^F = fluorescence wavelength.

3. Deviation tables


Table S2. Deviation table for the aminopalladation cascade terminated by Suzuki-Miyaura cross-coupling



Entry	Variation	Yield ^[a] [%]
1	None	56
2	DMF instead of MeCN	27
3	1,4-Dioxane instead of MeCN	7
4	PhMe instead of MeCN	5
5	CsF instead of DIPEA	17
6	Cs ₂ CO ₃ instead of DIPEA	32
7	Pd(P(3,5-(CF ₃) ₂ C ₆ H ₃) ₃) ₃ instead of Pd(PPh ₃) ₄	32
8	NEt ₃ instead of DIPEA	43
9	Additional JohnPhos (0.25 eq.)	24
10	Additional SPhos (0.25 eq.)	38
11	Additional dppe (0.25 eq.)	n.r.
12	boronic acid (3.00 eq.)	56 ^[b]

[a] Yields refer to GC-FID yields and are the combined yields of the (*E*)- and (*Z*)-isomer. [b] Reaction time: 1 h

Table S3. Deviation table for the aminopalladation cascade terminated by Sonogashira cross-coupling




Entry	Variation	Yield ^[a] [%]
1	None	40%
2	with CuI	36%
3	$\text{Pd}(\text{PPh}_3)_4$ as catalyst	30%
4	$\text{Pd}(\text{OAc})_2 + \text{PCy}_3$ as catalyst	11%
5	$\text{Pd}(\text{OAc})_2 + \text{P}(\text{C}_6\text{F}_5)_3$ as catalyst	8%
6	Cs_2CO_3 instead of Et_3N	25%
7	Et_2NH instead of Et_3N	23%
8	DIPEA instead of Et_3N	22%
9	1,4-Dioxane instead of THF	33%
10	MeCN instead of THF	27%
11	DMF instead of THF	25%

[a] Yields refer to NMR yields and are the combined yields of the (E)- and (Z)-isomer.


4. General Procedures

GP1: Sonogashira Reaction




In a flame-dried round bottom flask, $\text{PdCl}_2(\text{PPh}_3)_2$ (2 mol%) and CuI (2 mol%) were dissolved in a dry and degassed mixture of $\text{Et}_3\text{N}/\text{THF}$ (1:1, 4 mL/mmol). Then the aryl iodide (1.0 eq.) and the alkyne (1.1 – 2.0 eq.) were added at room temperature. The reaction was stirred at r.t. for 24 h – 72 h. After full conversion, the reaction was quenched by the addition of sat. aq. NH_4Cl -solution. The aqueous phase was extracted with EtOAc and the organic phase washed with brine and dried over Na_2SO_4 . The solvent was then removed *in vacuo*.

GP2: Oxime formation of benzophenone derivatives¹




The ketone was dissolved in MeOH (10 mL/mmol). Then pyridine (5.00 eq.) and hydroxylamine hydrochloride (1.50 eq.) were added and the reaction was stirred at $80\text{ }^\circ\text{C}$ for 8 – 16 h. The reaction was quenched by the addition of H_2O . The aqueous phase was extracted with EtOAc . The organic phase was washed with H_2O and brine, dried over Na_2SO_4 , filtered and concentrated *in vacuo*.

GP3: Oxime formation of acetophenone derivatives²




The ketone was dissolved in MeOH (10 mL/mmol). Then pyridine (5.00 eq.) and hydroxylamine hydrochloride (1.50 eq.) were added and the reaction was stirred at r.t. for 2 – 4 h. The reaction was quenched by the addition of H_2O . The aqueous phase was extracted with EtOAc . The organic phase was washed with H_2O and brine, dried over Na_2SO_4 , filtered and concentrated *in vacuo*.

GP4: Esterification of the oxime³



The oxime was dissolved in dry CH₂Cl₂ (3 mL/mmol) and cooled to 0 °C. After the addition of Et₃N (2.00 eq.), 2,3,4,5,6-pentafluorobenzoyl chloride (1.30 eq.) was added dropwise to the mixture. After full conversion of the starting material, the reaction was quenched by the addition of H₂O. The aqueous phase was extracted with CH₂Cl₂. The organic phase was washed with H₂O, dried over Na₂SO₄, filtered and concentrated *in vacuo*. If not stated otherwise, the residue was purified by flash column chromatography on silica gel.

GP5: *syn*-Aza-Suzuki-Miyaura Cascade




Precursor **1** (1.0 eq.), a boronic acid (3.0 eq.) and Pd(PPh₃)₄ (10mol%) were dissolved in MeCN (0.025 M) in a sealed microwave vial under an argon atmosphere. DIPEA (5.0 eq.) was added and the reaction stirred at 90 °C for the indicated time. After cooling down to r.t. the reaction was quenched with sat. aq. NH₄Cl-solution. The aqueous phase was extracted with EtOAc. The organic phase was washed with H₂O and brine, dried over Na₂SO₄, filtered and concentrated *in vacuo*.

Note:


No microwave was employed. Microwave vials were used, since they can be used as pressurized vessels and therefore allow reaction temperatures over the boiling point of the solvent.

GP6: Boc deprotection




According to a literature procedure, the *N*-Boc protected dipyrromethene was dissolved in dry MeOH (6 mL/mmol).⁴ After the addition of oxalyl chloride (3.00 eq.) at r.t. the reaction was stirred for the indicated time. The reaction was quenched by the addition of H₂O and the aqueous phase extracted with EtOAc. The organic phase was washed with H₂O and brine, dried over Na₂SO₄, filtered and concentrated *in vacuo*.

GP7: Formation of the BODIPY



The crude product of the deprotection step, was dissolved in dry toluene (10 mL/mmol) and cooled to 0 °C. Et₃N (10.0 eq.) was added and the reaction mixture stirred for 5 minutes at the same temperature. Then BF₃·OEt₂ (12.0 eq., 48%) was slowly added. The reaction was stirred at 50 °C for the indicated time. After completion, the reaction was quenched by the addition of H₂O. The aqueous phase was extracted with CH₂Cl₂ (3 x 50 mL). The organic phase was washed with H₂O, dried over Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel.

GP8: *syn*-Aza-Sonogashira Cascade




Precursor **1g** or **1h** (1.0 eq.), the alkyne (1.5 eq.) and Pd(P(3,5-(CF₃)₂C₆H₃)₃)₃ (15 mol%) were dissolved in dry THF (0.013 M) in a sealed microwave vial under an argon atmosphere. Et₃N

(5.0 eq.) was added and stirred at 110 °C for the indicated time. After cooling down to r.t. the reaction was quenched with sat. aq. NH₄Cl-solution. The aqueous phase was extracted with EtOAc. The organic phase was washed with H₂O and brine, dried over Na₂SO₄, filtered and concentrated *in vacuo*.

Note:


No microwave was employed. Microwave vials were used, since they can be used as pressurized vessels and therefore allow reaction temperatures over the boiling point of the solvent.

GP9: *N*-Boc deprotection with TFA



The starting material (1.0 eq.) was dissolved in a mixture of CH₂Cl₂/TFA (1:1, 0.05 M) and stirred at r.t. until full conversion of the starting material. Then the reaction was quenched at 0 °C with sat. aq. NaHCO₃ solution. The aqueous phase was extracted with CH₂Cl₂. The organic phase was washed with sat. aq. NaHCO₃ solution, water and brine, dried over Na₂SO₄, filtered and concentrated *in vacuo*.


GP10: BODIPY formation (for *meso*-alkynyl BODIPYs)



The crude product of the deprotection step, was dissolved in dry toluene (10 mL/mmol) and cooled to 0 °C. Et₃N (10.0 eq.) was added and the reaction mixture stirred for 5 minutes at the same temperature. Then BF₃·OEt₂ (12.00 eq., 48%) was slowly added. The reaction was stirred at 60 °C for the indicated time. After completion, the reaction was quenched by the addition of H₂O. The aqueous phase was extracted with CH₂Cl₂. The organic phase was washed with H₂O, dried over Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel.

5. Starting Material Synthesis

5.1. Overview



Scheme 1. Synthetic route to the starting material for the aminopalladation cascade

To prepare precursor **1**, we started from ketone **S1** and performed a Sonogashira cross-coupling reaction. The product **S2** was reacted with hydroxylamine hydrochloride under basic conditions to form the oxime **S3** which was further reacted with pentafluorobenzoyl chloride to get the desired precursor **1** (Scheme 1). The compounds and their synthesis were either literature known^{1,5} or are given in the following chapters (Figure 1).





Figure 1. Overview over all synthesized compounds for the precursor syntheses.

5.2. Ketone Precursors

Phenyl(2-((4-(trifluoromethyl)phenyl)ethynyl)phenyl)methanone (S2e)



2-Iodobenzophenone (1.55 g, 5.03 mmol, 1.00 eq.) and 1-ethynyl-4-(trifluoromethyl)benzene (0.74 mL, 5.26 mmol, 1.10 eq.) were reacted according to **GP1**. The residue was purified by flash column chromatography on silica gel (*n*-Pentane: EtOAc 50:1→25:1) to give the title compound (1.71 g, 4.87 mmol, 97%) as a beige solid.

m.p.: 79 °C.



¹H-NMR (400 MHz, CDCl₃): δ = 7.90 – 7.87 (m, 2 H), 7.66 – 7.44 (m, 9 H), 7.16 – 7.12 (m, 2 H).


¹³C-NMR (100 MHz, CDCl₃): δ = 196.7, 141.7, 137.3, 133.2, 132.7, 131.6, 130.4, 130.2, 130.0 (q, ²J_{C-F} = 32.6 Hz), 128.8, 128.7, 128.4, 126.4 – 126.3 (m), 125.0 (q, ³J_{C-F} = 3.8 Hz), 123.8 (q, ¹J_{C-F} = 272.2 Hz), 121.1, 93.4, 89.7.

¹⁹F-NMR (376 MHz, CDCl₃): δ = -63.29 (s).


IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 3062, 2114, 1653, 1603, 1317, 1157, 1109, 1056.

HRMS (ESI): C₂₂H₁₃F₃O calcd.: 373.0816 found: 373.0811, [M+Na]⁺.






¹⁹F-NMR, 376 MHz in CDCl₃



***tert*-Butyl 2-((2-benzoylphenyl)ethynyl)-1*H*-pyrrole-1-carboxylate (S2g)**



2-Iodobenzophenone (2.15 g, 7.00 mmol, 1.00 eq.) and *tert*-butyl 2-ethynyl-1*H*-pyrrole-1-carboxylate (1.47 g, 7.70 mmol, 1.10 eq.) were reacted according to **GP1**. The residue was purified by flash column chromatography on silica gel (*n*-Pentane: EtOAc 50:1) to give the title compound (2.28 g, 6.15 mmol, 88%) as a brown solid.



m.p.: 83 °C.

¹H-NMR (500 MHz, CDCl₃): δ = 7.88 – 7.84 (m, 2 H), 7.62 – 7.54 (m, 2 H), 7.53 – 7.39 (m, 5 H), 6.03 (t, *J* = 3.4 Hz, 1 H), 5.93 (dd, *J* = 3.5, 1.8 Hz, 1 H), 1.56 (s, 9 H).


¹³C-NMR (125 MHz, CDCl₃): δ = 196.9, 148.1, 141.3, 137.3, 133.0, 132.1, 130.3, 130.2, 128.7, 128.3, 127.9, 122.7, 122.2, 121.3, 114.6, 111.0, 90.9, 87.6, 84.2, 28.0.

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2979, 2928, 2159, 1737, 1657, 1309, 1112.

HRMS (ESI): C₂₄H₂₁NO₃ calcd.: 394.1414 found: 394.1415, [M+Na]⁺.



***tert*-Butyl 2-((2-acetylphenyl)ethynyl)-1*H*-pyrrole-1-carboxylate (S2h)**





2'-Iodoacetophenone (1.23 g, 5.00 mmol, 1.00 eq.) and *tert*-butyl 2-ethynyl-1*H*-pyrrole-1-carboxylate (1.00 g, 5.25 mmol, 1.05 eq.) were reacted according to **GP1**. The residue was purified by flash column chromatography on silica gel (*n*-Petane: EtOAc 50:1) to give the title compound (1.25 g, 4.07 mmol, 81%) as a yellow oil.

¹H-NMR (500 MHz, CDCl₃): δ = 7.75 (ddd, *J* = 7.8, 1.4, 0.5 Hz, 1 H), 7.62 (ddd, *J* = 7.7, 1.3, 0.5 Hz, 1 H), 7.46 (td, *J* = 7.5, 1.4 Hz, 1 H), 7.37 (ddd, *J* = 7.8, 7.4, 1.3 Hz, 1 H), 7.31 (dd, *J* = 3.3, 1.7 Hz, 1 H), 6.65 (dd, *J* = 3.5, 1.7 Hz, 1 H), 6.21 (t, *J* = 3.4 Hz, 1 H), 2.80 (s, 3 H), 1.60 (s, 9 H).

¹³C-NMR (125 MHz, CDCl₃): δ = 200.5, 148.1, 140.5, 133.6, 131.2, 128.7, 128.1, 123.1, 122.0, 121.2, 115.0, 111.3, 91.9, 87.7, 84.4, 30.1, 28.0.


IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2982, 2926, 2111, 1747, 1684, 1317, 1118.

HRMS (ESI): C₁₉H₁₉NO₃ calcd.: 332.1257 found: 332.1259, [M+Na]⁺.



5.3. Oxime Intermediates

(Z)-2-((4-Methoxyphenyl)ethynyl)phenyl(phenyl)methanone oxime (S3c)



Ketone **S2c** (1.43 g, 4.58 mmol, 1.00 eq.) was reacted according to **GP2**. The residue was purified by flash column chromatography on silica gel (*n*-Pentane: EtOAc 10:1→ 5:1) to give the title compound as a light green solid (1.20 g, 3.66 mmol, 85%).

Sample contains 16% of the (*E*)-isomer. Analytical data is only given for the main isomer.



m.p.: 116 °C.

¹H-NMR (400 MHz, CDCl₃): δ = 8.96 (s_{br}, 1 H), 7.69 – 7.59 (m, 1 H), 7.54 – 7.48 (m, 2 H), 7.44 – 7.39 (m, 2 H), 7.38 – 7.25 (m, 4 H), 7.16 – 7.05 (m, 2 H), 6.78 – 6.68 (m, 2 H), 3.73 (s, 3 H).


¹³C-NMR (100 MHz, CDCl₃): δ = 159.5, 157.5, 135.8, 135.4, 132.9, 132.0, 129.4, 128.8, 128.7, 128.3, 127.7, 127.1, 122.7, 115.0, 113.7, 93.4, 86.2, 55.2.

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 3229, 3058, 2899, 2837, 2215, 1597, 1506, 1446, 1244, 1023.

HRMS (ESI): C₂₂H₁₇NO₂ calcd.: 328.1332 found: 328.1333, [M+Na]⁺.



(E)-phenyl(2-((4-(trifluoromethyl)phenyl)ethynyl)phenyl)methanone oxime (S3e)



Ketone **S2e** (1.71 g, 4.87 mmol, 1.00 eq.) was reacted according to **GP2**. The residue was purified by flash column chromatography on silica gel (*n*-Pentane: EtOAc 20:1) to give the title compound (1.05 g, 2.89 mmol, 59%) as a blue solid.

m.p.: 131 °C, decomposition.



¹H-NMR (500 MHz, CDCl₃): δ = 7.71 – 7.61 (m, 3 H), 7.57 – 7.44 (m, 6 H), 7.40 – 7.32 (m, 4 H), 7.26 – 7.23 (m, 2 H).


¹³C-NMR (125 MHz, CDCl₃): δ = 157.5, 136.3, 135.3, 132.4, 131.7, 129.9 (q, ²J_{C-F} = 32.7 Hz), 129.6, 129.0, 128.9, 128.7, 128.4, 127.1, 126.7 (d, ⁴J_{C-F} = 1.4 Hz), 125.1 (q, ³J_{C-F} = 3.8 Hz), 123.9 (q, ¹J_{C-F} = 272.3 Hz), 121.6, 91.7, 89.8.

¹⁹F-NMR (470 MHz, CDCl₃): δ = -63.32 (s).


IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 3280, 3062, 2921, 2218, 1324, 1152, 1107, 1059, 995, 925, 837, 752, 686.

HRMS (ESI): C₂₂H₁₄F₃NO calcd.: 388.0925 found: 388.0921, [M+Na]⁺.





***tert*-Butyl (Z)-2-((2-((hydroxyimino)(phenyl)methyl)phenyl)ethynyl)-1*H*-pyrrole-1-carboxylate (S3g)**



Ketone **S2g** (3.41 g, 9.19 mmol, 1.00 eq.) was reacted according to **GP2**. Flash column chromatography on silica gel (n-Pentane/EtOAc 10:1) afforded the desired product (2.78 g, 7.20 mmol, 72%) as a light green solid.

Note: The reaction mixture slowly changes color from colorless to green within 6 h and turns blue, if heated for a longer period of time. The blue color indicates that the reaction has been heated for too long. If the reaction is blue, the product has undergone side reactions and the yield is diminished. The reaction should be terminated while being green. The leftover starting material can be recovered by column chromatography on silica gel.



m.p.: 100 °C.

¹H-NMR (500 MHz, CDCl₃): δ = 7.74 (s, 1 H), 7.65 – 7.61 (m, 1 H), 7.54 – 7.48 (m, 2 H), 7.45 – 7.38 (m, 2 H), 7.36 – 7.28 (m, 4 H), 7.20 (dd, J = 3.3, 1.7 Hz, 1 H), 6.14 (dd, J = 3.4, 1.7 Hz, 1 H), 6.06 (t, J = 3.4 Hz, 1 H), 1.56 (s, 9 H).

¹³C-NMR (125 MHz, CDCl₃): δ = 157.8, 148.2, 135.9, 135.4, 131.8, 129.3, 128.8, 128.6, 128.3, 127.9, 127.2, 122.7, 122.5, 121.4, 114.9, 111.1, 90.9, 85.5, 84.3, 28.0.


IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 3299, 3239, 1748, 1455, 1309, 1112.

HRMS (ESI): C₂₄H₂₂N₂O₃ calcd.: 409.1523 found: 409.1526, [M+Na]⁺.



5.4. Oximester Precursors

(*E*)-phenyl(2-(phenylethynyl)phenyl)methanone *O*-perfluorobenzoyl oxime (**1a**)



Oxime **S3a** (1.08 g, 3.63 mmol, 1.00 eq.) was treated according to **GP4**. The residue was purified by flash column chromatography on silica gel (*n*-Pentane: EtOAc 50:1) to give the title compound (1.29 g, 2.63 mmol, 72%) as a colorless solid.

The compound contains 30% of the (*Z*)-isomer. Analytical data is given for the major isomer.

m.p.: 131 °C.



¹H-NMR (500 MHz, CDCl₃): δ = 7.74 – 7.57 (m, 3 H), 7.53 – 7.35 (m, 6 H), 7.32 – 7.20 (m, 5 H).



¹³C-NMR (125 MHz, CDCl₃): δ = 166.2, 156.5, 146.65 – 146.19 (m), 144.60 – 144.18 (m), 142.56 – 142.19 (m), 138.92 – 138.26 (m), 136.59 (dt, J = 20.9, 7.2 Hz), 136.5, 135.2, 133.2, 132.2, 131.5, 130.5, 130.2, 129.8, 129.4, 128.6, 128.5, 128.2, 128.1, 128.0, 127.9, 122.4, 122.0, 106.82 (td, J = 16.4, 3.8 Hz), 94.0, 86.5.

¹⁹F-NMR (371 MHz, CDCl₃): δ = -137.07 – -137.34 (m), -148.47 (tt, J = 20.9, 4.8 Hz), -160.53 – -160.73 (m).


IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 3056, 2162, 1771, 1502, 1322, 1178, 992.

HRMS (ESI): C₂₈H₁₄F₅NO₂ calcd.: 514.0836 found: 514.0836, [M+Na]⁺.





(E)-1-(2-(Phenylethynyl)phenyl)ethan-1-one O-perfluorobenzoyl oxime (1b)



The corresponding ketone (0.87 g, 3.97 mmol, 1.00 eq.) was reacted according to **GP3** and the crude product was further submitted to **GP4**. The crude product was dissolved in CH₂Cl₂ and added dropwise to *n*-pentane at -80 °C. The precipitate was filtered off to give the title compound (1.13 g, 2.63 mmol, 66%) as a colorless solid.

m.p.: 147 °C.



¹H-NMR (500 MHz, CDCl₃): δ = 7.62 (dd, *J* = 7.6, 1.4 Hz, 1 H), 7.54 – 7.48 (m, 3 H), 7.45 (td, *J* = 7.6, 1.6 Hz, 1 H), 7.40 (td, *J* = 7.5, 1.4 Hz, 1 H), 7.36 (ddt, *J* = 5.0, 3.5, 1.9 Hz, 3 H), 2.58 (s, 3 H).


¹³C-NMR (125 MHz, CDCl₃): δ = 167.6, 156.4, 137.3, 133.1, 131.5, 129.9, 128.8, 128.7, 128.5, 128.5, 122.7, 122.1, 94.7, 87.1, 18.2.

¹⁹F-NMR (376 MHz, CDCl₃): δ = -137.37 (dq, *J* = 17.0, 5.9 Hz), -148.04 (tt, *J* = 20.9, 4.9 Hz), -159.99 – -160.66 (m).


IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 3077, 3029, 2216, 1762, 1495, 1321, 1192, 993, 877.

HRMS (ESI): C₂₃H₁₂F₅NO₂ calcd.: 452.0680 found: 452.0680, [M+Na]⁺.






¹⁹F-NMR, 376 MHz in CDCl₃



(E)-2-((4-Methoxyphenyl)ethynyl)phenyl)(phenyl)methanone O-perfluorobenzoyl oxime (1c)



Oxime **S3c** (1.19 g, 3.66 mmol, 1.00 eq.) was reacted according to **GP4**. The crude product was purified by flash column chromatography on silica gel (*n*-pentane: EtOAc 10:1 → 5:1) to give the title compound (1.64 g, 3.14 mmol, 69%) as a colorless solid.

The compound contains 15% of the (*Z*)-isomer. Analytical data is given for the major isomer.

m.p.: 120°C.



¹H-NMR (400 MHz, CDCl₃): δ = 7.71 – 7.67 (m, 2H), 7.63 – 7.59 (m, 1 H), 7.51 – 7.36 (m, 5 H), 7.30 – 7.26 (m, 1 H), 7.21 – 7.14 (m, 2 H), 6.79 – 6.75 (m, 2 H), 3.77 (s, 3 H).


¹³C-NMR (100 MHz, CDCl₃): δ = 166.3, 159.8, 135.0, 133.3, 133.1, 131.9, 131.4, 129.8, 129.4, 128.6, 128.6, 128.1, 127.9, 127.6, 122.4, 114.5, 113.8, 113.8, 94.2, 85.4, 55.2.

¹⁹F-NMR (376 MHz, CDCl₃): δ = -136.87 – -137.37 (m), -148.44 (tt, *J* = 21.0, 4.8 Hz), -160.43 – -160.83 (m).


IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 3067, 2908, 2832, 1753, 1499, 1323, 1187, 997.

HRMS (ESI): C₂₉H₁₆F₅NO₃ calcd.: 544.0943 found: 544.0944, [M+Na]⁺.






¹⁹F-NMR, 376 MHz in CDCl₃



(E)-1-(2-((4-Methoxyphenyl)ethynyl)phenyl)ethan-1-one O-perfluorobenzoyl oxime (1d)



Ketone **S2d** (0.86 g, 3.45 mmol, 1.00 eq.) was treated according to **GP3**. The crude product was then reacted according to **GP4**. A saturated CH_2Cl_2 solution of the crude product was added dropwise to *n*-pentane at $-80\text{ }^\circ\text{C}$. The solid was filtered off and dried in high vacuum to give the title compound (0.75 g, 1.63 mmol, 47% over two steps) as pale pink colored solid.

m.p.: $139\text{ }^\circ\text{C}$.



$^1\text{H-NMR}$ (500 MHz, CDCl_3): $d = 7.60$ (dt, $J = 7.6, 0.5$ Hz, 1 H), $7.52 - 7.50$ (m, 1 H), $7.46 - 7.41$ (m, 3 H), $7.39 - 7.35$ (m, 1 H), $6.90 - 6.87$ (m, 2 H), 3.83 (s, 3 H), 2.57 (s, 3 H).

$^{13}\text{C-NMR}$ (125 MHz, CDCl_3): $d = 167.8, 160.0, 156.5, 146.7 - 146.5$ (m, CF), $144.7 - 144.4$ (m, CF), $142.5 - 142.4$ (m, CF), $139.0 - 138.7$ (m, CF), $137.1, 137.0 - 136.6$ (m, CF), $133.0, 132.9, 129.9, 128.7, 128.2, 122.4, 114.8, 114.1, 107.3 - 106.9$ (m, CF), $94.9, 86.0, 55.3, 18.1$.

$^{19}\text{F-NMR}$ (470 MHz, CDCl_3): $d = -137.37 - -137.48$ (m, 2 F), -148.15 (tt, $J = 31.3, 4.6$ Hz, 1 F), $-160.24 - -160.39$ (m, 2 F).

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 2963, 2839, 2212, 1762, 1501, 1195, 994, 871, 771.


HRMS (ESI): $\text{C}_{24}\text{H}_{14}\text{F}_5\text{NO}_3$ calcd.: 482.0792 found: 482.0790, $[\text{M}+\text{Na}]^+$.




137.38
137.39
137.41
137.42
137.44
137.45
137.46
137.47

148.63
148.64
148.65
148.67
148.68
148.69
148.71
148.72
148.73


160.65
160.66
160.68
160.69
160.71
160.72
160.74
160.75
160.76



¹⁹F-NMR, 470 MHz in CDCl₃



(E)-Phenyl(2-((4-(trifluoromethyl)phenyl)ethynyl)phenyl)methanone O-perfluorobenzoyl oxime (1e)



Oxime **S3e** (1.05 g, 2.89 mmol, 1.00 eq.) was reacted according to **GP4**. The crude product was purified by flash column chromatography on silica gel (*n*-Pentane: EtOAc 50:1 → 20:1) to give the title compound (1.18 g, 2.12 mmol, 79%) as a grey solid.

m.p.: 144 °C.



¹H-NMR (500 MHz, CDCl₃): δ = 7.70 – 7.64 (m, 3 H), 7.52 – 7.46 (m, 5 H), 7.43 – 7.39 (m, 2 H), 7.35 – 7.28 (m, 3 H).


¹³C-NMR (125 MHz, CDCl₃): δ = 165.4, 156.5, 146.6 – 146.2 (m, CF), 144.5 – 144.3 (m, CF), 142.6 – 142.2 (m, CF), 138.8 – 138.5 (m, CF), 136.8 – 136.4 (m, CF), 135.5, 133.1, 132.3, 131.8, 131.6, 130.2 (q, ²J_{C-F} = 32.7 Hz) 129.5, 128.7, 128.7, 128.6, 128.0, 126.3 – 126.1 (m), 125.1 (q, ³J_{C-F} = 3.8 Hz), 123.8 (q, ¹J_{C-F} = 272.2 Hz), 121.3, 106.7 (td, J = 24.4, 3.9 Hz), 92.4, 88.7.

¹⁹F-NMR (470 MHz, CDCl₃): δ = -63.37 (s), -137.26 – -137.37 (m), -148.22 (tt, J = 20.9, 4.8 Hz), -160.40 – -160.55 (m).


IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 3068, 2322, 1751, 1493, 1320, 1191, 1109.

HRMS (ESI): C₂₉H₁₃F₈NO₂ calcd.: 582.0716 found: 582.0712, [M+Na]⁺.





(E)-1-(2-((4-(Trifluoromethyl)phenyl)ethynyl)phenyl)ethan-1-one O-perfluorobenzoyl oxime (1f)



Ketone **S2f** (0.86 g, 3.45 mmol, 1.00 eq.) was treated according to **GP3**. The crude product was then reacted according to **GP4**. A saturated CH_2Cl_2 solution of the crude product was added dropwise to *n*-pentane at $-80\text{ }^\circ\text{C}$. The solid was filtered off and dried in high vacuum to give the title compound (0.75 g, 1.63 mmol, 47% over two steps) as colorless solid.

m.p.: $103\text{ }^\circ\text{C}$.



$^1\text{H-NMR}$ (400 MHz, CDCl_3): δ = 7.67 – 7.60 (m, 5H), 7.54 (dd, J = 7.2, 1.8 Hz, 1H), 7.50 – 7.41 (m, 2H), 2.57 (s, 3H).


$^{13}\text{C-NMR}$ (100 MHz, CDCl_3): δ = 167.1, 156.3, 146.9 -146.7 (m, CF), 144.3 - 144.1 (m, CF), 137.4, 136.7-136.4(m, CF), 133.3, 131.7, 130.38 (q, $^2J_{\text{C-F}}$ = 32.7 Hz), 126.50 (d, $^4J_{\text{C-F}}$ = 1.4 Hz), 129.9, 129.1, 128.8, 125.37 (q, $^3J_{\text{C-F}}$ = 3.8 Hz) 123.82 (d, $^1J_{\text{C-F}}$ 272.3 Hz), 121.3, 107.1-106.8 (m, CF), 18.1.

$^{19}\text{F-NMR}$ (376 MHz, CDCl_3): δ = -63.31, -137.45 (dp, J = 16.9, 5.9 Hz), -147.81 (tt, J = 20.9, 4.8 Hz), -160.02 – -160.33 (m).


IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 3075, 2930, 2323, 1762, 1494, 1317, 1188, 1132.

HRMS (ESI): $\text{C}_{24}\text{H}_{11}\text{F}_8\text{NO}_2$ calcd.: 520.0554 found: 520.0554, $[\text{M}+\text{Na}]^+$.





***tert*-Butyl (*E*)-2-((2-(((perfluorobenzoyl)oxy)imino)(phenyl)methyl)phenyl)ethynyl)-1*H*-pyrrole-1-carboxylate (1g)**



Oxime **S3g** (2.78 g, 7.20 mmol, 1.00 eq.) was reacted according to **GP4**. A concentrated solution of the crude product in CH₂Cl₂ was added dropwise to *n*-pentane at -40 °C. The colorless solid was filtered off, washed with *n*-pentane and dried to give the product as a colorless solid (1.67 g, 2.88 mmol). The *n*-pentane was removed in vacuo and the residue was purified by flash column chromatography on silica gel (*n*-Pentane: EtOAc 25:1) to give the title compound (1.56 g, 2.69 mmol) as a light brown solid. Both fractions were combined (3.23 g, 5.57 mmol, 77%).

m.p.: 134 °C.



¹H-NMR (400 MHz, CDCl₃): δ = 7.69 – 7.65 (m, 2 H), 7.64 – 7.60 (m, 1 H), 7.49 – 7.35 (m, 6 H), 7.30 – 7.26 (m, 1 H), 7.20 (dd, *J* = 3.3, 1.7 Hz, 1 H), 6.22 (dd, *J* = 3.5, 1.7 Hz, 1 H), 6.08 (t, *J* = 3.4 Hz, 1 H), 1.54 (s, 9 H).


¹³C-NMR (125 MHz, CDCl₃): δ = 166.1, 156.5, 148.0, 146.5 (m), 144.4 (m), 142.3 (m), 138.6 (m), 136.6 (m), 135.0, 133.3, 131.7, 131.3, 129.3, 128.7, 128.5, 127.9, 127.8, 122.7, 122.3, 121.7, 114.5, 111.2, 106.9 (m), 90.0, 86.5, 84.1, 27.9.

¹⁹F-NMR (376 MHz, CDCl₃): δ = -136.86 – -137.38 (m), -148.51 (tt, *J* = 20.8, 4.7 Hz), -160.47 – -160.96 (m).


IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2986, 2934, 2211, 1742, 1496, 1318, 1186, 1115, 996.

HRMS (ESI): C₃₁H₂₁F₅N₂O₄ calcd.: 603.1316 found: 603.1316, [M+Na]⁺.






¹⁹F-NMR, 376 MHz in CDCl₃



***tert*-Butyl (*E*)-2-((2-(1-(((perfluorobenzoyl)oxy)imino)ethyl)phenyl)ethynyl)-1*H*-pyrrole-1-carboxylate (**1h**)**



Ketone **S2h** (1.08 g, 3.50 mmol, 1.00 eq.) was reacted according to **GP3**. The crude product was then reacted according to **GP4**. A saturated CH₂Cl₂ solution of the residue was added dropwise to *n*-pentane at -80 °C. The solid was filtered and dried to give the title compound (1.40 g, 2.70 mmol, 68%) as a colorless solid.

m.p.: 146 °C.



¹H-NMR (500 MHz, CDCl₃): δ = 7.60 (ddd, *J* = 7.7, 1.4, 0.6 Hz, 1 H), 7.52 (ddd, *J* = 7.6, 1.5, 0.6 Hz, 1 H), 7.42 (td, *J* = 7.6, 1.5 Hz, 1 H), 7.37 (td, *J* = 7.6, 1.4 Hz, 1 H), 7.30 (dd, *J* = 3.3, 1.7 Hz, 1 H), 6.60 (dd, *J* = 3.5, 1.7 Hz, 1 H), 6.20 (t, *J* = 3.4 Hz, 1 H), 2.58 (s, 3 H), 1.58 (s, 9 H).


¹³C-NMR (125 MHz, CDCl₃): δ = 168.0, 156.5, 148.1, 137.1, 132.9, 129.8, 128.8, 128.3, 123.0, 122.3, 121.3, 114.8, 111.3, 90.5, 87.2, 84.4, 27.9, 18.2.

¹⁹F-NMR (470 MHz, CDCl₃): δ = -137.14 – -137.47 (m), -148.25 (tt, *J* = 20.8, 4.7 Hz), -160.23 – -160.64 (m).


IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2984, 2931, 2158, 1750, 1491, 1321, 1122, 994.

HRMS (ESI): C₂₆H₁₉F₅N₂O₄ calcd.: 541.1157 found: 541.1156, [M+Na]⁺.






^{19}F -NMR, 470 MHz in CDCl_3



6. BODIPYs

6.1. *meso*-Aryl BODIPYs

5,5-Difluoro-7,12-diphenyl-5*H*-5 λ^4 ,6 λ^4 -pyrrolo[1',2':3,4][1,3,2]diazaborinino[6,1-*a*]isoindole (5a)



The corresponding precursor **1a** (491 mg, 1.00 mmol, 1.00 eq.) was reacted with *N*-Boc-2-pyrroloboronic acid (633 mg, 3.00 mmol, 3.00 eq.) according to **GP5** for 2.5 h. The crude product was reacted according to **GP6** for 16 h. Without further purification, the product was subjected to **GP7** for 10 minutes. The product was purified by flash column chromatography on silica gel (*n*-pentane: EtOAc 20:1) The title compound was obtained as a dark red solid (179.40 mg, 455.00 μ mol, 46%).

m.p.: 217 °C.

¹H-NMR (400 MHz, CDCl₃): δ = 7.92 – 7.85 (m, 2 H), 7.68 – 7.50 (m, 10 H), 7.29 – 7.18 (m, 1 H), 6.51 (dt, J = 7.6, 0.9 Hz, 1 H), 6.41 (dd, J = 3.9, 1.2 Hz, 1 H), 6.35 (dd, J = 3.8, 2.2 Hz, 1 H).

¹³C-NMR (101 MHz, CDCl₃): δ = 161.2, 139.6, 136.3, 135.7, 134.3, 133.8, 132.8, 131.1, 130.7, 129.99 (t, J = 3.2 Hz), 129.8, 129.7, 129.5, 129.2, 128.8, 128.3, 126.5, 124.7, 123.9, 122.2, 114.9.

¹⁹F-NMR (376 MHz, CDCl₃): δ = -137.63 (dd, J = 60.2, 29.0 Hz).



¹¹B-NMR (128 MHz, CDCl₃): δ = 1.43 (t, J = 30.4 Hz).


IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2921, 2853, 1607, 1554, 1520, 1392, 1033.

HRMS (ESI): C₂₅H₁₇BF₂N₂ calcd.: 417.1345 found: 417.1349, [M+Na]⁺.



UV/Vis (0.0041 mg/mL in CH₂Cl₂): λ_{\max} [nm] (log ϵ) = 540 (4.70).


Emission (CH₂Cl₂): λ_{\max} (nm) = 571.






¹⁹F-NMR, 376 MHz in CDCl₃





UV-Vis and normalized fluorescence spectra of 5a at room temperature in CH_2Cl_2 .

5,5-Difluoro-7-methyl-12-phenyl-5H-5λ⁴,6λ⁴-pyrrolo[1',2':3,4][1,3,2]diazaborinino[6,1-a]isoindole (5b)



Precursor **1b** (43 mg, 0.10 mmol, 1.0 eq.) was reacted with *N*-Boc-2-pyrroleboronic acid (64 mg, 0.30 mmol, 3.0 eq.) according to **GP5** for 1h. The crude product was then subjected to **GP6** (reaction time: 16 h). Without further purification the product was reacted according to **GP7** for 10 min. After purification by flash column chromatography on silica gel (*n*-pentane/EtOAc 10:1 → 5:1 and *n*-pentane/CH₂Cl₂ 3:1 → 1:1) the title compound was obtained as an orange solid (11 mg, 0.033 mmol, 33%).

m.p.: 207 °C

¹H-NMR (400 MHz, CDCl₃): δ = 7.74 (dt, *J* = 7.9, 1.1 Hz, 1 H), 7.62 – 7.52 (m, 4 H), 7.50 – 7.46 (m, 2 H), 7.30 (ddd, *J* = 8.0, 7.1, 1.0 Hz, 1 H), 7.22 (ddd, *J* = 8.2, 7.1, 1.2 Hz, 1 H), 6.50 (dt, *J* = 8.1, 1.0 Hz, 1 H), 6.35 – 6.30 (m, 2 H), 3.01 (t, *J* = 1.3 Hz, 3 H).

¹³C-NMR (125 MHz, CDCl₃): δ = 162.8, 137.7, 135.9, 134.1, 134.1, 133.5, 132.8, 131.4, 129.4, 129.2, 129.1, 128.7, 126.4, 123.0, 122.5, 122.4, 114.3, 13.33 (t, *J* = 2.9 Hz).

¹⁹F-NMR (376 MHz, CDCl₃): δ = -144.63 (dd, *J* = 61.9, 30.3 Hz, 2 F).



¹¹B-NMR (128 MHz, CDCl₃): δ = 1.38 (t, *J* = 31.1 Hz, 1 B).


IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 3065, 2921, 2854, 1580, 1393, 1069, 1027, 722.

HRMS (ESI): C₂₀H₁₅BF₂N₂ calcd.: 333.1369 found: 333.1370, [M+Na]⁺.



UV/Vis (0.0040 mg/mL in CH₂Cl₂): λ_{max} [nm] (log ε) = 517 (4.58).

Emission (CH₂Cl₂): λ_{max} (nm) = 542.







¹⁹F-NMR, 376 MHz in CDCl₃




¹¹B-NMR, 128 MHz in CDCl₃





UV-Vis and normalized fluorescence spectra of **5b** at room temperature in CH_2Cl_2 .

**5,5-Difluoro-12-(4-methoxyphenyl)-7-phenyl-5H-
5 λ^4 ,6 λ^4 pyrrolo[1',2':3,4][1,3,2]diazaborinino[6,1-a]isoindole (5c)**



First step (**Method A**):

Precursor **1c** (58 mg, 0.10 mmol, 1.0 eq.) was reacted with *N*-Boc-2-pyrroloboronic acid (64 mg, 0.30 mmol, 3.0 eq.) according to **GP5** for 1 h.

First step (**Method B**):

Precursor **1g** (58.01 mg, 0.10 mmol, 1.00 eq.) was reacted with *p*-methoxyphenyl boronic acid (45.59 mg, 0.30 mmol, 3.00 eq.) according to **GP5** for 1 h.

Continuing steps (**Methods A + B**):

The crude product was subjected to **GP6** (reaction time: 16 h). Without further purification the product was reacted according to **GP7** (reaction time: 10 min). After purification by flash column chromatography on silica gel (*n*-pentane: EtOAc 10:1 → 5:1) the title compound was obtained as a bright red solid (**method A**: 16.4 mg, 0.039 mmol, 39%; **method B**: 9.3 mg, 22 μ mol, 22%).

m.p.: 217 °C.

¹H-NMR (500 MHz, CDCl₃): δ = 7.94 – 7.83 (m, 2 H), 7.65 – 7.57 (m, 4 H), 7.54 (dd, *J* = 2.2, 1.3 Hz, 1 H), 7.51 – 7.45 (m, 2 H), 7.31 – 7.22 (m, 2 H), 7.15 – 7.06 (m, 2 H), 6.73 – 6.65 (m, 1 H), 6.46 (dd, *J* = 3.8, 1.2 Hz, 1 H), 6.35 (dd, *J* = 3.8, 2.2 Hz, 1 H), 3.96 (s, 3 H).

¹³C-NMR (125 MHz, CDCl₃): δ = 160.7, 139.8, 136.4, 135.5, 134.1, 131.0, 130.8, 130.6, 130.0, 129.9, 128.3, 126.4, 126.4, 124.6, 123.9, 122.3, 114.9, 114.2, 55.5.

¹⁹F-NMR (470 MHz, CDCl₃): δ = -137.74 (dd, *J* = 59.8, 28.3 Hz).



¹¹B-NMR (160 MHz, CDCl₃): δ = 1.41 (t, *J* = 30.4 Hz).



IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 3109, 2919, 2845, 1603, 1553, 1389, 1248, 1181, 1021.


HRMS (ESI): C₂₆H₁₉BF₂N₂O calcd.: 425.1631 found: 425.1633, [M+Na]⁺.

UV/Vis (0.0069 mg/mL in CH₂Cl₂): λ_{\max} [nm] (log ϵ) = 541 (4.67).

Emission (CH₂Cl₂): λ_{\max} (nm) = 574.








UV-Vis and normalized **fluorescence spectra** of **5c** at room temperature in CH_2Cl_2 .

5,5-Difluoro-12-(4-methoxyphenyl)-7-methyl-5H-5λ⁴,6λ⁴-pyrrolo[1',2':3,4][1,3,2]diazaborinino[6,1-a]isoindole (5d)



First step (**Method A**):

Precursor **1d** (45 mg, 0.10 mmol, 1.0 eq.) was reacted with *N*-Boc-2-pyrroleboronic acid (64 mg, 0.30 mmol, 3.0 eq.) according to **GP5** for 2.5 h.

First step (**Method B**):

Precursor **1h** (52 mg, 0.10 mmol, 1.00 eq.) was reacted with *p*-methoxyphenyl boronic acid (45.59 mg, 0.30 mmol, 3.00 eq.) according to **GP5** for 1 h.

Continuing steps (**Methods A + B**):

The crude product was then subjected to **GP6** (reaction time: 16 h). Without further purification, the product was reacted according to **GP7** (reaction time: 15 min). After purification by flash column chromatography on silica gel (*n*-pentane/EtOAc 10:1 → 8:1), the title compound was obtained as light red solid (**method A**: 15 mg, 0.042 mmol, 42%; **method B**: 18 mg, 0.050 mmol, 50%).

m.p.: 143 °C.

¹H-NMR (500 MHz, CDCl₃): δ = 7.75 (dt, *J* = 7.9, 1.1 Hz, 1 H), 7.55 (t, *J* = 1.8 Hz, 1 H), 7.45 – 7.39 (m, 2 H), 7.33 – 7.23 (m, 2 H), 7.15 – 7.03 (m, 2 H), 6.68 (dt, *J* = 8.0, 1.0 Hz, 1 H), 6.39 – 6.29 (m, 2 H), 3.94 (s, 3 H), 3.01 (t, *J* = 1.2 Hz, 3 H).

¹³C-NMR (125 MHz, CDCl₃): δ = 162.4, 160.6, 137.8, 136.0, 134.0, 133.8, 132.8, 131.4, 130.7, 129.3, 126.3, 126.2, 122.9, 122.5, 114.2, 114.1, 55.4, 13.3.

¹⁹F-NMR (470 MHz, CDCl₃): δ = -144.77 (dd, *J* = 61.7, 29.8 Hz).



¹¹B-NMR (160 MHz, CDCl₃): δ = 1.36 (t, *J* = 31.1 Hz).



IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2924, 2845, 1572, 1515, 1391, 1249, 1077, 1025.


HRMS (ESI): C₂₁H₁₇BF₂N₂O calcd.: 385.1299 found: 385.1297, [M+Na]⁺.

UV/Vis (0.0072 mg/mL in CH₂Cl₂): λ_{max} [nm] (log ε) = 517 (4.58).

Emission (CH₂Cl₂): λ_{max} (nm) = 543.








UV-Vis and normalized fluorescence spectra of 5d at room temperature in CH₂Cl₂.

5,5-Difluoro-7-phenyl-12-(4-(trifluoromethyl)phenyl)-5H-5λ⁴,6λ⁴-pyrrolo[1',2':3,4][1,3,2]diazaborinino[6,1-a]isoindole (5e)



First step (**Method A**):

Precursor **1e** (49 mg, 0.10 mmol, 1.0 eq.) was reacted with *N*-Boc-2-pyrroloboronic acid (64 mg, 0.30 mmol, 3.0 eq.) according to **GP5** for 1 h.

First step (**Method B**):

Precursor **1g** (58 mg, 0.10 mmol, 1.0 eq.) was reacted with (4-(trifluoromethyl)phenyl)boronic acid (57 mg, 0.30 mmol, 3.0 eq.) according to **GP5** for 1 h.

Continuing steps (**Methods A + B**):

The crude product was reacted according to **GP6** for 16 h. Without further purification the product was subjected to **GP7** (reaction time: 15 min). After purification by column chromatography on silica gel (*n*-pentane/EtOAc 50:1 → 20:1, *n*-pentane/EtOAc/CH₂Cl₂ 20:1:1 and *n*-pentane/EtOAc/toluene 12:1:1) the title compound was obtained as bright red solid (**method A**: 4.1 mg, 0.009 mmol, 9%; **method B**: 9.2 mg, 0.020 mmol, 20%).

m.p.: 233 °C.

¹H-NMR (500 MHz, CDCl₃): δ = 7.91 – 7.86 (m, 4 H), 7.70 (d, *J* = 7.9 Hz, 2 H), 7.65 – 7.61 (m, 4 H), 7.58 – 7.56 (m, 1 H), 7.32 – 7.27 (m, 2 H), 6.48 – 6.45 (m, 1 H), 6.37 – 6.35 (m, 1 H), 6.34 – 6.32 (m, 1 H).

¹³C-NMR (125 MHz, CDCl₃): δ = 162.2, 138.1 – 138.0 (m), 137.4, 136.1, 136.0, 133.3, 133.0, 131.8 (q, ²*J*_{C-F} = 33.1 Hz, Cq), 131.5, 130.9, 130.0 (t, ⁴*J*_{C-F} = 3.1 Hz), 129.9, 129.6, 129.5, 128.4, 126.9, 125.9 (q, ³*J*_{C-F} = 3.8 Hz), 125.7, 123.7, 121.9, 115.2.

¹⁹F-NMR (470 MHz, CDCl₃): δ = -63.02 (s, 3 F), -145.26 (q, *J* = 29.4 Hz, 2 F).



¹¹B-NMR (160 MHz, CDCl₃): δ = 1.39 (t, *J* = 30.2 Hz, 1 B).



IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1567, 1397, 1322, 1123, 908, 849, 745, 688.


HRMS (ESI): C₂₆H₁₆BF₅N₂ calcd.: 485.1224 found: 485.1221, [M+Na]⁺.

UV/Vis (0.0036 mg/mL in CH₂Cl₂): λ_{max} [nm] (log ε) = 542 (4.63).

Emission (CH₂Cl₂): λ_{max} (nm) = 575.








UV-Vis and normalized **fluorescence spectra** of **5e** at room temperature in CH_2Cl_2 .

5,5-Difluoro-7-methyl-12-(4-(trifluoromethyl)phenyl)-5H-5λ⁴,6λ⁴-pyrrolo[1',2':3,4][1,3,2]diazaborinino[6,1-a]isoindole (5f)



First step (**Method A**):

Precursor **1f** (50 mg, 0.10 mmol, 1.0 eq.) was reacted with (*N*-Boc-2-pyrroleboronic acid (64 mg, 0.30 mmol, 3.0 eq.) according to **GP5** for 1 h.

First step (**Method B**):

Precursor **1h** (52 mg, 0.10 mmol, 1.0 eq.) was reacted with (4-(trifluoromethyl)phenyl)boronic acid (57 mg, 0.30 mmol, 3.0 eq.) according to **GP5** for 1 h.

Continuing steps (**Methods A + B**):

The crude product was subjected to **GP6** (reaction time: 16 h). Without further purification, the product was then reacted according to **GP7** (reaction time: 10 min). After purification by flash column chromatography on silica gel (*n*-pentane/EtOAc 10:1 → 5:1 and *n*-pentane/CH₂Cl₂ 3:1 → 1:1) the title compound was obtained as a bright red solid (**method A**: 8.8 mg, 22 μmol, 22%, **method B**: 7.9 mg, 0.020 mmol, 20%).

m.p.: 209 °C.

¹H-NMR (500 MHz, CDCl₃): δ = 7.87 – 7.81 (m, 2 H), 7.78 (dt, *J* = 7.9, 1.0 Hz, 1 H), 7.67 – 7.61 (m, 2 H), 7.57 (t, *J* = 1.7 Hz, 1 H), 7.34 (ddd, *J* = 8.0, 7.2, 1.0 Hz, 1 H), 7.28 (ddd, *J* = 8.2, 7.1, 1.2 Hz, 1 H), 6.45 (dt, *J* = 8.1, 0.9 Hz, 1 H), 6.35 (dd, *J* = 3.8, 2.3 Hz, 1 H), 6.24 (dd, *J* = 3.8, 1.2 Hz, 1 H), 3.03 (t, *J* = 1.3 Hz, 3 H).

¹³C-NMR (125 MHz, CDCl₃): δ = 163.9, 137.8 (d, ⁴*J*_{C-F} = 1.2 Hz), 135.6, 134.6, 133.0, 133.0, 131.9, 131.68 (d, ²*J*_{C-F} = 32.8 Hz), 129.8, 128.9, 126.8, 125.79 (q, ³*J*_{C-F} = 3.7 Hz), 123.89 (d, ¹*J*_{C-F} = 272.4 Hz), 123.3, 122.4, 122.0, 114.6, 13.4.

¹⁹F-NMR (470 MHz, CDCl₃): δ = -63.04, -144.59 (dd, *J* = 62.3, 30.4 Hz).



¹¹B-NMR (160 MHz, CDCl₃): δ = 1.35 (t, *J* = 30.9 Hz).



IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 3105, 3078, 2926, 1590, 1528, 1393, 1325, 1159, 1035.


HRMS (ESI): C₂₁H₁₄BF₅N₂ calcd.: 381.1180 found 381.1183, [M+Na]⁺.

UV/Vis (0.0022 mg/mL in CH₂Cl₂): λ_{max} [nm] (log ε) = 519 (4.55).

Emission (CH₂Cl₂): λ_{max} (nm) = 545.








UV-Vis and normalized **fluorescence spectra** of **5f** at room temperature in CH_2Cl_2 .

5,5-Difluoro-7-phenyl-12-(thien-2-yl)-5H-5 λ ^4,6 λ ^4-pyrrolo[1',2':3,4][1,3,2]diazaborinino[6,1-a]isoindole (5g)



Precursor **1g** (58 mg, 0.10 mmol, 1.0 eq.) was reacted with thien-2-ylboronic acid (38 mg, 0.30 mmol, 3.0 eq.) according to **GP5** for 1 h. The crude product was then subjected to **GP6** (reaction time: 16 h). The product was reacted without further purification according to **GP7** (reaction time: 10 min). After purification by flash column chromatography on silica gel (*n*-pentane/EtOAc 20:1 → 10:1 and *n*-pentane/CH₂Cl₂ 3:1 → 1:1) the title compound was obtained as a dark red solid (10 mg, 0.025 mmol, 25%).

m.p.: 238 °C.

¹H-NMR (500 MHz, CDCl₃): δ = 7.88 (dd, *J* = 6.7, 3.0 Hz, 2 H), 7.66 (dd, *J* = 5.1, 1.2 Hz, 1 H), 7.63 – 7.57 (m, 4 H), 7.53 (dd, *J* = 2.2, 1.3 Hz, 1 H), 7.36 – 7.26 (m, 4 H), 6.76 – 6.71 (m, 1 H), 6.64 (d, *J* = 3.2 Hz, 1 H), 6.36 (dd, *J* = 3.9, 2.2 Hz, 1 H).

¹³C-NMR (125 MHz, CDCl₃): δ = 161.8, 136.1, 135.8, 134.1, 133.9, 132.8, 132.2, 131.4, 130.8, 130.0, 130.0, 130.0, 129.8, 129.7, 128.3, 128.2, 127.5, 126.8, 124.8, 123.9, 122.5, 115.0.

¹⁹F-NMR (470 MHz, CDCl₃): δ = -137.83 (d, *J* = 30.5 Hz).



¹¹B-NMR (160 MHz, CDCl₃): δ = 1.38 (t, *J* = 30.2 Hz).


IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 3109, 3065, 2919, 2319, 1608, 1560, 1386, 1131, 1029.

HRMS (ESI): C₂₃H₁₅BF₂N₂S calcd.: 423.0915 found: 423.0913, [M+Na]⁺.



UV/Vis (0.0020 mg/mL in CH₂Cl₂): λ_{max} [nm] (log ε) = 551 (4.67).

Emission (CH₂Cl₂): λ_{max} (nm) = 573.







¹⁹F-NMR, 470 MHz in CDCl₃




¹¹B-NMR, 160 MHz in CDCl₃





UV-Vis and normalized fluorescence spectra of **5g** at room temperature in CH_2Cl_2 .

**5,5-Difluoro-7-methyl-12-(thien-2-yl)-5H-5 λ^4 ,6 λ^4 -pyrrolo[1',2':3,4][1,3,2]diazaborin-
ino[6,1-*a*]isoindole (5h)**



Precursor **1h** (52 mg, 0.10 mmol, 1.0 eq.) was reacted with thien-2-ylboronic acid (128 mg, 0.30 mmol, 3.0 eq.) according to **GP5** for 1 h. The crude product was subjected to **GP6** (reaction time: 16 h). Without further purification, the product was then reacted according to **GP7** (reaction time: 15 min). After purification by flash column chromatography on silica gel (*n*-pentane/EtOAc 20:1) the title compound was obtained as light red solid (12 mg, 0.036 mmol, 36%).

m.p.: 153 °C.

¹H-NMR (500 MHz, CDCl₃): δ = 7.78 – 7.73 (m, 1 H), 7.62 (dd, *J* = 5.0, 1.3 Hz, 1 H), 7.54 (t, *J* = 1.7 Hz, 1 H), 7.36 – 7.30 (m, 2 H), 7.28 – 7.23 (m, 2 H), 6.75 – 6.68 (m, 1 H), 6.55 – 6.52 (m, 1 H), 6.36 (dd, *J* = 3.8, 2.3 Hz, 1 H), 3.01 (s, 3 H).

¹³C-NMR (125 MHz, CDCl₃): δ = 163.6, 135.7, 134.3, 133.8, 133.7, 132.9, 131.8, 130.3, 130.3, 129.5, 128.0, 127.4, 126.7, 123.1, 122.7, 122.5, 114.4, 13.4.

¹⁹F-NMR (376 MHz, CDCl₃): δ = -144.64 (dd, *J* = 61.6, 30.1 Hz).



¹¹B-NMR (160 MHz, CDCl₃): δ = 1.32 (t, *J* = 30.9 Hz).


IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 103, 3068, 2922, 2854, 2110, 1572, 1523, 1387, 1337, 1209, 1072.

HRMS (ESI): C₁₈H₁₃BF₂N₂S calcd.: 361.0753 found: 361.0755, [M+Na]⁺.



UV/Vis (0.0019 mg/mL in CH₂Cl₂): λ_{max} [nm] (log ε) = 526 (4.50).

Emission (CH₂Cl₂): λ_{max} (nm) = 541.







¹⁹F-NMR, 376 MHz in CDCl₃




¹¹B-NMR, 160 MHz in CDCl₃





UV-Vis and normalized fluorescence spectra of 5h at room temperature in CH₂Cl₂.

6,6-Difluoro-8-phenyl-13-(4-(trifluoromethyl)phenyl)-6H-6λ⁴,7λ⁴-isoindolo[2',1':1,6][1,3,2]diazaborinino[3,4-a]indole (5i)



Precursor **1e** (58 mg, 0.10 mmol, 1.0 eq.) was reacted with *N*-Boc (indol-2-yl)boronic acid (78 mg, 0.30 mmol, 3.0 eq.) according to **GP5** for 1 h. The crude product was then reacted according to **GP6** (reaction time: 16 h). Without further purification the product was subjected to **GP7** (reaction time: 20 min). After purification by flash column chromatography on silica gel (*n*-pentane/EtOAc 8:1 → 5:1 and *n*-pentane/EtOAc/PhMe 5:1:1) the title compound was obtained as a bright red solid (9 mg, 17 μmol, 17%).

m.p.: 273 °C.

¹H-NMR (500 MHz, CDCl₃): δ = 7.97 (dd, *J* = 7.6, 2.0 Hz, 2 H), 7.92 (d, *J* = 7.9 Hz, 2 H), 7.75 (d, *J* = 7.9 Hz, 2 H), 7.73 – 7.70 (m, 1 H), 7.69 – 7.64 (m, 4 H), 7.47 (dt, *J* = 8.1, 0.9 Hz, 2 H), 7.39 (td, *J* = 7.5, 1.3 Hz, 1 H), 7.37 – 7.34 (m, 1 H), 7.28 – 7.23 (m, 1 H), 7.01 (ddd, *J* = 8.0, 6.8, 0.9 Hz, 1 H), 6.54 (td, *J* = 4.0, 1.3 Hz, 2 H).

¹³C-NMR (125 MHz, CDCl₃): δ = 165.5, 145.0, 137.9 (d, ⁴*J*_{C-F} = 1.1 Hz), 137.2, 136.9, 135.9, 134.1, 133.4, 132.3, 131.9 (d, ²*J*_{C-F} = 32.7 Hz), 131.5, 130.2, 130.1, 130.0 (t, *J* = 3.3 Hz), 129.1, 128.5, 128.1, 127.4, 125.9 (q, ³*J*_{C-F} = 3.7 Hz), 125.8, 123.8 (d, ¹*J*_{C-F} = 272.5 Hz), 122.8, 122.5, 121.1, 116.5, 114.8.

¹⁹F-NMR (376 MHz, CDCl₃): δ = -62.96, -137.76 (dd, *J* = 59.8, 19.7 Hz).



¹¹B-NMR (128 MHz, CDCl₃): δ = 2.10 (t, *J* = 31.0 Hz).



IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2922, 2854, 2323, 1721, 1577, 1458, 1329, 1103, 1018.


HRMS (ESI): C₃₀H₁₈BF₅N₂ calcd.: 535.1375 found: 535.1375, [M+Na]⁺.

UV/Vis (0.0027 mg/mL in CH₂Cl₂): λ_{max} [nm] (log ε) = 547 (4.60).

Emission (CH₂Cl₂): λ_{max} (nm) = 599.








UV-Vis and normalized **fluorescence spectra** of **5i** at room temperature in CH₂Cl₂.

6,6-Difluoro-8-methyl-13-(4-(trifluoromethyl)phenyl)-6H-6λ⁴,7λ⁴-isoindolo[2',1':1,6][1,3,2]diazaborinino[3,4-a]indole (5j)



Precursor **1f** (58 mg, 0.10 mmol, 1.0 eq.) was reacted with *N*-Boc (indol-2-yl)boronic acid (78 mg, 0.30 mmol, 3.0 eq.) according to **GP5** for 1 h. The crude product was subjected to **GP6** (reaction time: 16 h). Without further purification the product was reacted according to **GP7** (reaction time: 20 min). After purification by flash column chromatography on silica gel (*n*-pentane/EtOAc 10:1 and *n*-pentane/CH₂Cl₂ 3:2) the title compound was obtained as a bright orange solid (5.8 mg, 13 μmol, 13%).

m.p.: 266 °C.

¹H-NMR (500 MHz, CDCl₃): δ = 7.89 (d, *J* = 8.0 Hz, 2 H), 7.84 (dt, *J* = 7.9, 0.9 Hz, 2 H), 7.80 (d, *J* = 8.4 Hz, 1 H), 7.69 (d, *J* = 7.9 Hz, 2 H), 7.49 (dd, *J* = 8.1, 1.1 Hz, 1 H), 7.44 (td, *J* = 7.6, 0.9 Hz, 1 H), 7.36 (ddd, *J* = 8.2, 7.3, 1.1 Hz, 1 H), 7.32 (ddd, *J* = 8.2, 6.8, 1.2 Hz, 1 H), 7.04 (ddd, *J* = 8.0, 6.9, 0.9 Hz, 1 H), 6.53 (dt, *J* = 8.0, 0.8 Hz, 2 H), 6.47 (s, 1H), 3.13 (s, 3 H).

¹³C-NMR (125 MHz, CDCl₃): δ = 167.4, 144.4, 137.7, 137.0, 135.3, 135.2, 134.1, 132.7, 132.6, 130.1, 131.8 (d, ²*J*_{C-F} = 32.8 Hz), 130.0, 128.1, 127.0, 125.9 (q, ³*J*_{C-F} = 3.7 Hz), 123.8, 123.8 (d, ¹*J*_{C-F} = 272.4 Hz), 122.9, 122.3, 121.0, 115.3, 114.5, 13.8.

¹⁹F-NMR (470 MHz, CDCl₃): δ = -63.04, -145.13 (dd, *J* = 61.9, 27.1 Hz).



¹¹B-NMR (160 MHz, CDCl₃): δ = 2.00 (t, *J* = 31.8 Hz).



IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2922, 2854, 2323, 1591, 1518, 1329, 1125, 993.


HRMS (ESI): C₂₅H₁₆BF₅N₂ calcd.: 451.1399 found: 451.1407, [M+H]⁺.

UV/Vis (0.0054 mg/mL in CH₂Cl₂): λ_{max} [nm] (log ε) = 519 (4.59).

Emission (CH₂Cl₂): λ_{max} (nm) = 567.








UV-Vis and normalized fluorescence spectra of **5j** at room temperature in CH_2Cl_2 .

**11,11-Difluoro-4,9-diphenyl-11H-10 λ^4 ,11 λ^4 -
pyrazolo[1',5':3,4][1,3,2]diazaborinino[6,1-a]isoindole (5k)**



Precursor **1g** (49 mg, 0.10 mol, 1.0 eq.) was reacted with (*N*-Boc Pyrazol-5-yl)boronic acid (64 mg, 0.30 mmol, 3.0 eq.) according to **GP5** for 1 h. The crude product was subjected to **GP6** (reaction time: 16 h). Without further purification the crude product was reacted according to **GP7** (reaction time: 15 min). After purification by flash column chromatography on silica gel (*n*-pentane : EtOAc 2:1 → 1:1) the title compounds was obtained as yellow solid (6.4 mg, 0.017 mmol, 17%).

m.p.: 200 °C.

¹H-NMR (500 MHz, CDCl₃): δ = 7.98 – 7.95 (m, 2 H), 7.73 – 7.60 (m, 8 H), 7.58 – 7.53 (m, 2 H), 7.40 (dtd, *J* = 19.2, 7.3, 1.1 Hz, 2 H), 6.70 (d, *J* = 7.7 Hz, 1 H), 6.20 (d, *J* = 1.7 Hz, 1 H).

¹³C-NMR (125 MHz, CDCl₃): δ = 170.0, 143.0, 141.3, 136.6, 135.9, 134.5, 133.5, 133.2, 132.0, 130.08 (dd, *J* = 6.7, 3.2 Hz), 129.2, 128.8, 128.7, 128.6, 128.5, 126.3, 123.4, 111.5.

¹⁹F-NMR (470 MHz, CDCl₃): δ = -140.36 (dd, *J* = 53.0, 22.3 Hz).

¹¹B-NMR (160 MHz, CDCl₃): δ = 1.26 (t, *J* = 27.0 Hz).



IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 3063, 2921, 2853, 2114, 1712, 1597, 1479, 1437, 1110.

HRMS (ESI): C₂₄H₁₆BF₂N₃ calcd.: 396.1478 found: 396.1483, [M+Na]⁺.


UV/Vis (0.0027 mg/mL in CH₂Cl₂): λ_{max} [nm] (log ε) = 459 (4.20).

Emission (CH₂Cl₂): λ_{max} (nm) = 530.

7.97
7.96
7.95
7.72
7.71
7.69
7.68
7.67
7.66
7.66
7.65
7.65
7.64
7.63
7.63
7.61
7.57
7.56
7.55
7.55
7.43
7.42
7.40
7.39
7.38
7.38
7.36
7.36
6.69
6.20




¹H-NMR, 500 MHz in CDCl₃






170.01
142.95
141.28
136.60
135.89
134.54
133.90
133.87
131.97
130.12
130.07
130.04
129.22
128.95
128.87
128.67
128.46
126.26
123.39
111.52


77.26 CDCl3
76.75 CDCl3



¹³C-NMR, 125 MHz in CDCl₃








UV-Vis and normalized **fluorescence spectra** of **5k** at room temperature in CH₂Cl₂.

**11,11-Difluoro-9-methyl-4-phenyl-11*H*-10 λ^4 ,11 λ^4 -
pyrazolo[1',5':3,4][1,3,2]diazaborinino[6,1-*a*]isoindole (5l)**



Precursor **1h** (43 mg, 0.10 mmol, 1.0 eq.) was reacted with (*N*-Boc pyrazol-5-yl)boronic acid (64 mg, 0.30 μ mol, 3.0 eq.) according to **GP5** for 1 h. The crude product was subjected to **GP6** (reaction time: 16 h). Without further purifications the product was reacted according to **GP7** (reaction time: 15 min). After purification by flash column chromatography on silica gel (*n*-pentane/EtOAc 1:1) the title compound was obtained as dark green solid (7.0 mg, 0.021 mmol, 21%).

m.p.: 192 °C.

¹H-NMR (400 MHz, CDCl₃): δ = 7.84 (dt, *J* = 7.8, 1.0 Hz, 1 H), 7.72 (d, *J* = 1.8 Hz, 1 H), 7.68 – 7.56 (m, 3 H), 7.52 – 7.43 (m, 3 H), 7.38 (ddd, *J* = 8.0, 7.3, 1.1 Hz, 1 H), 6.69 (dt, *J* = 8.0, 0.9 Hz, 1 H), 6.16 (d, *J* = 1.8 Hz, 1 H), 3.13 (t, *J* = 1.3 Hz, 3 H).

¹³C-NMR (100 MHz, CDCl₃): δ = 171.9, 142.9, 136.0, 134.4, 134.1, 133.8, 133.5, 133.2, 130.0, 129.1, 128.8, 128.7, 124.0, 123.5, 111.1, 29.7, 14.1.

¹⁹F-NMR (376 MHz, CDCl₃): δ = -147.66 (dd, *J* = 54.0, 25.3 Hz, 2 F).



¹¹B-NMR (128 MHz, CDCl₃): δ = 1.17 (t, *J* = 27.5 Hz).


IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2923, 2853, 2115, 1738, 1616, 1445, 1221, 1093, 995.

HRMS (ESI): C₁₉H₁₄BF₂N₃ calcd.: 334.1322 found: 334.1326, [M+H]⁺.



UV/Vis (0.0088 mg/mL in CH₂Cl₂): λ_{\max} [nm] (log ϵ) = 434 (4.21).

Emission (CH₂Cl₂): λ_{\max} (nm) = 507.







¹⁹F-NMR, 376 MHz in CDCl₃



¹¹B-NMR, 128 MHz in CDCl₃






UV-Vis and normalized fluorescence spectra of **5I** at room temperature in CH_2Cl_2 .

6.2. meso-Alkynyl-BODIPYs

5,5-Difluoro-7-phenyl-12-(phenylethynyl)-5H-5λ⁴,6λ⁴-pyrrolo[1',2':3,4][1,3,2]diazaborinino[6,1-a]isoindole (6a)



Precursor **1h** (58 mg, 0.10 mmol, 1.0 eq.) was reacted with phenyl acetylene (15 mg, 0.15 mmol, 1.5 eq.) according to **GP8** for 3 h. The crude product was subjected to **GP9**. Without further purification the product was reacted according to **GP10**. After purification by flash column chromatography on silica gel (n-Pentane/EtOAc 99:1) the title compound was obtained as a red solid (16 mg, 0.038 mmol, 38%).

m.p.: 219 °C.

¹H-NMR (500 MHz, CDCl₃): δ = 8.65 (dt, *J* = 8.1, 0.8 Hz, 1 H), 7.90 (d, *J* = 2.2 Hz, 1 H), 7.89 (d, *J* = 4.0 Hz, 1 H), 7.75 (dd, *J* = 7.6, 2.3 Hz, 2 H), 7.71 – 7.64 (m, 2 H), 7.61 (dd, *J* = 4.7, 1.6 Hz, 3 H), 7.54 – 7.48 (m, 3 H), 7.46 – 7.45 (m, 1 H), 7.42 (ddd, *J* = 8.0, 7.1, 0.9 Hz, 1 H), 7.15 (dd *J* = 3.6, 0.8, 1 H), 6.42 (dd, *J* = 3.8, 2.2 Hz, 1 H).

¹³C-NMR (125 MHz, CDCl₃): δ = 160.6, 135.7, 134.7, 133.0, 132.8, 132.6, 132.2, 132.1, 130.9, 130.3, 130.14 (t, *J* = 3.4 Hz), 129.6, 128.9, 128.3, 127.3, 125.1, 122.6, 121.7, 121.7, 118.9, 114.8, 104.1, 84.9.

¹⁹F-NMR (470 MHz, CDCl₃): δ = -137.81 (dd, *J* = 58.9, 27.5 Hz).



¹¹B-NMR (160 MHz, CDCl₃): δ = 1.32 (t, *J* = 30.0 Hz).



IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2923, 2856, 2318, 2203, 1560, 1396, 1186, 1126, 1075, 1031.


HRMS (ESI): C₂₇H₁₇BF₂N₂ calcd.: 419.1526, found: 419.1527, [M+H]⁺.

UV/Vis (0.0058 mg/mL in CH₂Cl₂): λ_{max} [nm] (log ε) = 582 (4.34).

Emission (CH₂Cl₂): λ_{max} (nm) = 617.








UV-Vis and normalized **fluorescence spectra** of **6a** at room temperature in CH₂Cl₂.

12-(Cyclopropylethynyl)-5,5-difluoro-7-phenyl-5*H*-5λ4,6λ4-pyrrolo[1',2':3,4][1,3,2]di-azaborinino[6,1-*a*]isoindole



Precursor **1g** (58 mg, 0.10 mmol, 1.0 eq.) was reacted with ethynylcyclopropane (6.0 mg, 0.15 mmol, 1.5 eq.) according to **GP8** for 3 h. The crude product was subjected to **GP9**. Without further purification the product was reacted according to **GP10**. After purification by flash column chromatography on silica gel (n-Pentane/EtOAc 99:1) the title compound was obtained as a red solid (9.0 mg, 0.023 mmol, 23%).

m.p.: 186 °C

¹H-NMR (500 MHz, CDCl₃): δ = 8.49 (dt, *J* = 8.1, 0.9 Hz, 1H), 7.89 – 7.83 (m, 2H), 7.68 – 7.56 (m, 5H), 7.42 – 7.37 (m, 2H), 6.99 (dd, *J* = 3.8, 1.3 Hz, 1H), 6.37 (dd, *J* = 3.8, 2.2 Hz, 1H), 1.82 – 1.75 (m, 1H), 1.20 – 1.09 (m, 4H).

¹³C-NMR (125 MHz, CDCl₃): δ = 159.7, 135.7, 134.3, 133.6, 132.9, 132.4, 132.0, 130.8 (t, *J* = 3.2 Hz), 130.2, 129.8, 128.4, 127.2, 125.0, 122.3, 121.7, 120.4, 114.6, 111.2, 72.2, 10.1, 1.5.

¹⁹F-NMR (470 MHz, CDCl₃): δ = -137.53 (dd, *J* = 59.3, 28.3 Hz)


¹¹B-NMR (160 MHz, CDCl₃): δ = 1.05 (t, *J* = 30.1 Hz)

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2923, 2205, 1606, 1557, 1520, 1464, 1391, 1347, 1279, 1252, 1184, 1129, 1097, 1067, 1026, 977, 914, 740.


HRMS (ESI): C₂₄H₁₇BF₂N₂ calcd.: 383:1526 found: 383.1530, [M+H]⁺.

UV/Vis (0.0030 mg/mL in CH₂Cl₂): λ_{max} [nm] (log ε) = 570 (4.60).


Emission (CH₂Cl₂): λ_{max} (nm) = 604.




137.48
137.56
137.62




¹⁹F-NMR, 470 MHz in CDCl₃




1.24
1.05
0.86




¹¹B-NMR, 160 MHz in CDCl₃





UV-Vis and normalized fluorescence spectra of **6a** at room temperature in CH_2Cl_2 .

12-((*tert*-Butyldimethylsilyl)ethynyl)-5,5-difluoro-7-phenyl-5*H*-5λ⁴,6λ⁴-pyrrolo[1',2':3,4][1,3,2]diazaborinino[6,1-*a*]isoindole (6c)



Precursor **1g** (58 mg, 0.10 mmol, 1.0 eq.) was reacted with *tert*-butyl(ethynyl)dimethylsilane (21 mg, 0.15 mmol, 1.5 eq.) according to **GP8** for 3 h. The crude product was subjected to **GP9**. Without further purification the product was reacted according to **GP10**. After purification by flash column chromatography on silica gel (n-Pentane/EtOAc 99:1) the title compound was obtained as a red solid (35 mg, 0.077 mmol, 77%).

m.p.: 137 °C.

¹H-NMR (500 MHz, CDCl₃): δ = 8.65 (dt, *J* = 8.2, 0.9 Hz, 1 H), 7.89 – 7.85 (m, 2 H), 7.67 (dt, *J* = 8.1, 1.0 Hz, 1 H), 7.65 – 7.58 (m, 4 H), 7.43 – 7.39 (m, 2 H), 7.04 (dd, *J* = 3.6, 1.1 Hz, 1 H), 6.39 (dd, *J* = 3.8, 2.2 Hz, 1 H), 1.10 (s, 9 H), 0.37 (s, 6 H).

¹³C-NMR (125 MHz, CDCl₃): δ = 160.9, 135.7, 134.8, 133.3, 132.6, 132.0, 130.9, 130.1, 129.5, 128.3, 127.4, 125.1, 122.8, 121.9, 118.3, 114.7, 110.8, 99.9, 26.2, 16.9, 1.0, -4.8.

¹⁹F-NMR (376 MHz, CDCl₃): δ = -137.85 (dd, *J* = 58.9, 27.6 Hz).



¹¹B-NMR (160 MHz, CDCl₃): δ = 1.26 (t, *J* = 30.0 Hz).



IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 3108, 3058, 2939, 2851, 2114, 1755, 1559, 1390, 1119.

HRMS (ESI): C₂₇H₂₇BF₂N₂Si calcd.: 479.1902 found: 479.1904, [M+Na]⁺.


UV/Vis (0.0022 mg/mL in CH₂Cl₂): λ_{max} [nm] (log ε) = 580 (4.53).

Emission (CH₂Cl₂): λ_{max} (nm) = 613.






¹¹B-NMR (160 MHz, CDCl₃).



UV-Vis and normalized fluorescence spectra of **6c** at room temperature in CH_2Cl_2 .

12-((*tert*-Butyldimethylsilyl)ethynyl)-5,5-difluoro-7-methyl-5*H*-5λ⁴,6λ⁴-pyrrolo[1',2':3,4][1,3,2]diazaborinino[6,1-*a*]isoindole (6d)



Precursor **1h** (52 mg, 0.10 mmol, 1.0 eq.) was reacted with *tert*-butyl(ethynyl)dimethylsilane (21 mg, 0.15 mmol, 1.5 eq.) according to **GP8** for 3 h. The crude product was subjected to **GP9**. Without further purification, the product was reacted according to **GP10**. After purification by flash column chromatography on silica gel (n-Pentane/EtOAc 99:1) the title compound was obtained as a red solid (19 mg, 0.048 mmol, 48%).

m.p.: 156 °C

¹H-NMR (500 MHz, CDCl₃): δ = 8.51 (dt, *J* = 8.1, 0.9 Hz, 1H), 7.79 (dt, *J* = 7.9, 1.0 Hz, 1H), 7.62 (ddd, *J* = 8.1, 7.1, 1.0 Hz, 1H), 7.46 – 7.42 (m, 2H), 6.96 (dd, *J* = 3.7, 1.3 Hz, 1H), 6.38 (dd, *J* = 3.7, 2.3 Hz, 1H), 2.98 (s, 3H), 1.08 (s, 9H), 0.34 (s, 6H).

¹³C-NMR (125 MHz, CDCl₃): δ = 163.0, 135.4, 133.6, 133.0, 132.9, 132.7, 132.5, 127.4, 123.4, 123.1, 120.7, 116.8, 114.2, 109.9, 99.7, 26.3, 16.9, 13.5, -4.7.

¹⁹F-NMR (470 MHz, CDCl₃): δ = -144.42 (dd, *J* = 60.8, 29.1 Hz).



¹¹B-NMR (160 MHz, CDCl₃): δ = 0.97 (t, *J* = 30.6 Hz).



IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 3660, 2981, 2888, 1740, 1574, 1471, 1394, 1236, 1144, 1086, 968, 831.


HRMS (ESI): C₂₂H₂₅BF₂N₂Si calcd.: 395.1921 found: 395.1918, [M+H]⁺.

UV/Vis (0.0046 mg/mL in CH₂Cl₂): λ_{max} [nm] (log ε) = 553 (4.33).

Emission (CH₂Cl₂): λ_{max} (nm) = 583.








UV-Vis and normalized fluorescence spectra of **6d** at room temperature in CH_2Cl_2 .

5,5-Difluoro-12-(pent-1-yn-1-yl)-7-phenyl-5*H*-5λ⁴,6λ⁴-pyrrolo[1',2':3,4][1,3,2]diazaborinino[6,1-*a*]isoindole (6e)



Precursor **1g** (58 mg, 0.10 mmol, 1.0 eq.) was reacted with pent-1-yne (10 mg, 0.15 mmol, 1.5 eq.) according to **GP8** for 3 h. The crude product was subjected to **GP9**. Without further purification, the product was reacted according to **GP10**. After purification by flash column chromatography on silica gel (n-Pentane/EtOAc 99:1) the title compound was obtained as a red solid (26 mg, 0.068 mmol, 68%).

m.p.: 132 °C

¹H-NMR (500 MHz, CDCl₃): δ = 8.56 (dt, *J* = 8.2, 0.9 Hz, 1H), 7.89 – 7.84 (m, 2H), 7.68 – 7.56 (m, 5H), 7.42 – 7.38 (m, 2H), 7.04 (dd, *J* = 3.8, 1.3 Hz, 1H), 6.38 (dd, *J* = 3.8, 2.2 Hz, 1H), 2.73 (t, *J* = 7.0 Hz, 2H), 1.85 (h, *J* = 7.2 Hz, 2H), 1.19 (t, *J* = 7.4 Hz, 3H).

¹³C-NMR (125 MHz, CDCl₃): δ = 160.1, 135.8, 134.5, 133.7, 132.9, 132.5, 132.0, 130.9, 130.2 (t, *J* = 3.2 Hz), 129.8, 128.4, 127.3, 125.0, 122.5, 121.9, 120.2, 114.7, 107.5, 76.7, 22.5, 22.0, 13.9.

¹⁹F-NMR (470 MHz, CDCl₃): δ = -137.51 (dd, *J* = 59.4, 28.1 Hz).



¹¹B-NMR (160 MHz, CDCl₃): δ = 1.06 (t, *J* = 30.1 Hz).



IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2922, 2853, 2220, 1608, 1558, 1461, 1391, 1347, 1280, 1219, 1184, 1127, 1097, 977, 784, 754, 697.


HRMS (ESI): C₂₄H₁₉BF₂N₂ calcd.: 385.1682 found: 385.1682, [M+H]⁺.

UV/Vis (0.0056 mg/mL in CH₂Cl₂): λ_{max} [nm] (log ε) = 564 (4.14).

Emission (CH₂Cl₂): λ_{max} (nm) = 602.








UV-Vis and normalized fluorescence spectra of **6e** at room temperature in CH₂Cl₂.

5,5-Difluoro-12-(pent-1-yn-1-yl)-7-methyl-5*H*-5λ⁴,6λ⁴-pyrrolo[1',2':3,4][1,3,2]diazaborinino[6,1-*a*]isoindole (6f)



Precursor **1h** (52 mg, 0.10 mmol, 1.0 eq.) was reacted with pent-1-yne (10 mg, 0.15 mmol, 1.5 eq.) according to **GP8** for 3 h. The crude product was subjected to **GP9**. Without further purification, the product was reacted according to **GP10**. After purification by flash column chromatography on silica gel (n-Pentane/EtOAc 99:1) the title compound was obtained as a red solid (6 mg, 0.019 mmol, 19%).

m.p.: 132 °C

¹H-NMR (500 MHz, CDCl₃): δ = 8.43 (dt, *J* = 8.1, 0.9 Hz, 1H), 7.78 (dt, *J* = 7.9, 1.0 Hz, 1H), 7.62 (ddd, *J* = 8.1, 7.1, 1.0 Hz, 1H), 7.45 – 7.41 (m, 2H), 6.96 (dd, *J* = 3.7, 1.3 Hz, 1H), 6.37 (dd, *J* = 3.7, 2.3 Hz, 1H), 2.97 (s, 3H), 2.69 (t, *J* = 7.0 Hz, 2H), 1.82 (q, *J* = 7.2 Hz, 2H), 1.16 (t, *J* = 7.4 Hz, 3H).

¹³C-NMR (126 MHz, CDCl₃): δ = 162.0, 135.4, 133.2, 132.6, 132.5, 132.5, 132.4, 127.1, 123.3, 122.6, 120.5, 118.4, 114.1, 106.4, 76.3, 22.4, 22.0, 13.8, 13.4 (t, *J* = 2.9 Hz).

¹⁹F-NMR (470 MHz, CDCl₃): δ = -144.53 (dd, *J* = 60.9, 29.8 Hz).



¹¹B-NMR (160 MHz, CDCl₃): δ = 0.99 (t, *J* = 30.7 Hz).



IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2960, 2927, 2853, 2218, 1731, 1568, 1524, 1393, 1374, 1251, 1139, 1063, 981, 752.


HRMS (ESI): C₁₉H₁₇BF₂N₂ calcd.: 323.1526 found: 323.1527, [M+H]⁺.

UV/Vis (0.0042 mg/mL in CH₂Cl₂): λ_{max} [nm] (log ε) = 544 (4.38).

Emission (CH₂Cl₂): λ_{max} (nm) = 574.







UV-Vis and normalized **fluorescence spectra** of **6f** at room temperature in CH_2Cl_2 .

7. Crystal Structure Determinations

BODIPYs **5a**, **5b**, and **5l**

Crystals of **5a**, **5b** and **5l** were obtained by vapour diffusion of *n*-hexane into solutions of the compounds in chloroform. Crystals were mounted in inert oil on Hampton loops and transferred to the cold gas stream of a Rigaku/OD XtaLAB Synergy diffractometer. Mirror-focussed Mo- $K\alpha$ radiation was employed for the intensity measurements of **5a** and **5l**, whereas for **5b** mirror-focussed Cu- $K\alpha$ radiation was used. Absorption corrections were implemented on the basis of multi-scans. The structure was refined anisotropically on F^2 using the program SHELXL-2018.⁶ Hydrogen atoms were included using rigid methyl groups or a riding model starting from calculated positions. *Exceptions/special details*: For **5b**, an extinction correction was performed; the SHELX extinction parameter refined to 0.00086(19). For **5l**, the methyl hydrogen atoms at C1 were indistinct. This group was therefore refined as a rigid group using a regular hexagon of half-occupied hydrogen positions (command "AFIX 127"). Compounds **5b** and **5l** are effectively isotopic.

Crystallographic data are summarized in Table S4, and ellipsoid plots are presented as Fig. S1-4. Additionally, complete data have been deposited with the Cambridge Crystallographic Data Centre under the numbers CCDC 2298671-3. Copies of the data can be obtained free of charge from www.ccdc.cam.ac.uk/data_request/cif.

BODIPY **6e**

Crystals of **6e** were obtained at room temperature by slow solvent evaporation from a solution of the compound dissolved in a mixture of pentane and dichloromethane. A red, plate-shaped crystal of **6e** was mounted on a MiTeGen micromount with perfluoroether oil. Data were collected from a shock-cooled single crystal at 100(2) K on a Bruker D8 VENTURE dual wavelength Mo/Cu three-circle diffractometer with a microfocus sealed X-ray tube using mirror optics as the monochromator and a Bruker PHOTON III detector. The diffractometer was equipped with an Oxford Cryostream 800 low temperature device and used Mo $K\alpha$ radiation ($\lambda = 0.71073 \text{ \AA}$). All data were integrated with SAINT, and a multi-scan absorption correction using TWINABS was applied.^{7,8} The structure was solved by direct methods using SHELXT and refined by full-matrix least-squares methods against F^2 by SHELXL-2019/2.^{6,9} All non-hydrogen atoms were refined with anisotropic displacement parameters. All hydrogen atoms were refined isotropically on calculated positions using a riding model with their U_{iso} values constrained to 1.5 times the U_{eq} of their pivot atoms for terminal sp^3 carbon atoms and 1.2 times for all other carbon atoms.

Crystallographic data for the structures reported here have been deposited with the Cambridge Crystallographic Data Centre.¹⁰ CCDC 2284407 contains the supplementary crystallographic

data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures. This report and the CIF file were generated using FinalCif.¹¹

Table S4: Crystallographic data and structure refinement details for compounds **5a**, **5b**, **5l**, and **6e**.

Compound	5a	5b	5l	6e
CCDC number	2298671	2298672	2298673	2284407
Formula	C ₂₅ H ₁₇ BF ₂ N ₂	C ₂₀ H ₁₅ BF ₂ N ₂	C ₁₉ H ₁₄ BF ₂ N ₃	C ₂₄ H ₁₉ BF ₂ N ₂
<i>M_r</i>	394.21	332.15	333.14	384.22
Cryst. size (mm)	0.15 x 0.15 x 0.06	0.09 x 0.07 x 0.02	0.17 x 0.10 x 0.04	0.15 x 0.12 x 0.06
Crystal system	monoclinic	monoclinic	monoclinic	triclinic
Space group	<i>P</i> 2 ₁ / <i>c</i>	<i>P</i> 2 ₁ / <i>c</i>	<i>P</i> 2 ₁ / <i>c</i>	<i>P</i> $\bar{1}$ (2)
Temperature (°C)	-173	-173	-173	-173
<i>a</i> (Å)	11.1893(2)	11.2668(3)	11.2238(3)	7.0095(10)
<i>b</i> (Å)	10.9459(2)	15.3965(4)	15.6385(4)	10.7904(16)
<i>c</i> (Å)	15.6815(3)	9.5029(3)	9.2476(3)	12.520(3)
α (°)	90	90	90	97.995(7)
β (°)	92.820(2)	106.696(3)	106.535	93.450(7)
γ (°)	90	90	90	95.353(7)
<i>V</i> (Å ³)	1918.29	1578.97	1556.04	931.1(3)
<i>Z</i>	4	4	4	2
<i>D_x</i> (Mg m ⁻³)	1.365	1.397	1.422	1.371
λ (Å)	0.71073	1.54184	0.71073	0.71073
μ (mm ⁻¹)	0.09	0.81	0.10	0.09
Transmissions	0.809 – 1.000	0.800 – 1.000	0.938 – 1.000	0.986 – 0.995
<i>F</i> (000)	816	688	688	400
2 θ _{max}	71.9	155.5	72.6	61.2
Refl. measured	149697	64031	142487	121443
Refl. indep.	8633	3337	7548	5698
<i>R</i> _{int}	0.032	0.048	0.045	0.0657
Parameters	271	228	227	264
Restraints	0	0	0	0
<i>wR</i> (<i>F</i> ² , all refl.)	0.120	0.099	0.131	0.117
<i>R</i> (<i>F</i> , >4 σ (<i>F</i>))	0.026	0.043	0.045	0.046
<i>S</i>	1.12	1.15	1.05	1.05
Max. $\Delta\rho$ (e Å ⁻³)	0.53, -0.23	0.26, -0.16	0.63, -0.24	0.40, -0.28




Fig. S1. The molecule of compound **5a** in the crystal. Ellipsoids correspond to 50% probability levels.




Fig. S2. The molecule of compound **5b** in the crystal. Ellipsoids correspond to 50% probability levels.




Fig. S3. The molecule of compound **5I** in the crystal. Ellipsoids correspond to 50% probability levels.




Fig. S4. The molecule of compound **6e** in the crystal. Ellipsoids correspond to 50% probability levels.

8. References

- 1 H.-S. Yeom, Y. Lee, J.-E. Lee and S. Shin, *Org. Biomol. Chem.*, 2009, **7**, 4744–4752.
- 2 W. S. Kim, V. M. Espinoza Castro, A. Abiad, M. Ko, A. Council, A. Nguyen, L. Marsalla, V. Lee, T. Tran, A. S. Petit and H. J. P. de Lijser, *J. Org. Chem.*, 2021, **86**, 693–708.
- 3 W.-X. Wei, Y. Li, Y.-T. Wen, M. Li, X.-S. Li, C.-T. Wang, H.-C. Liu, Y. Xia, B.-S. Zhang, R.-Q. Jiao and Y.-M. Liang, *J. Am. Chem. Soc.*, 2021, **143**, 7868–7875.
- 4 N. George, S. Ofori, S. Parkin and S. G. Awuah, *RSC Adv.*, 2020, **10**, 24017–24026.
- 5 W.-N. Jiang, Q.-L. Zhao, W.-S. Cheng, J.-A. Xiao, H.-Y. Xiang, K. Chen and H. Yang, *Org. Chem. Front.*, 2021, **8**, 3250–3254.
- 6 G. M. Sheldrick, *Acta Cryst.*, 2015, **C71**, 3–8.
- 7 Bruker, *SAINTE V8.40B*, Bruker AXS Inc., Madison, Wisconsin, USA.
- 8 L. Krause, R. Herbst-Irmer, G. M. Sheldrick and D. Stalke, *J. Appl. Cryst.*, 2015, **48**, 3–10.
- 9 G. M. Sheldrick, *Acta Cryst.*, 2015, **A71**, 3–8.
- 10 C. R. Groom, I. J. Bruno, M. P. Lightfoot and S. C. Ward, *Acta Cryst.*, 2016, **B72**, 171–179.
- 11 D. Kratzert, *FinalCif. V123*, <https://dkratzert.de/finalcif.html>.